高级检索
当前位置: 首页 > 详情页

ADAR2 functions as a tumor suppressor via editing IGFBP7 in esophageal squamous cell carcinoma

文献详情

资源类型:
机构: [1]Sun Yat Sen Univ, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Ctr Canc, Guangzhou 510060, Guangdong, Peoples R China; [2]Qingdao Univ, Affiliated Hosp, Cent Lab, Qingdao 266000, Shandong, Peoples R China; [3]Third Mil Med Univ, Xinqiao Hosp, Dept Endocrinol, Chongqing 400037, Peoples R China; [4]NIMH, Unit Stat Genom, Div Intramural Res Programs, NIH, Bethesda, MD 20892 USA; [5]Sun Yat Sen Univ, State Key Lab Oncol South China, Ctr Canc, Bldg 2,Room 903,651 Dongfeng Rd East, Guangzhou 510060, Guangdong, Peoples R China
出处:
ISSN:

关键词: ADAR2 esophageal neoplasms IGFBP7 RNA editing RNA sequencing

摘要:
Esophageal squamous cell carcinoma (ESCC), one of the most aggressive cancers, is characterized by heterogeneous genetic and epigenetic changes. Recently, A-to-I RNA editing, catalyzed by adenosine deaminases acting on RNA (ADARs), was found to be aberrantly regulated during tumorigenesis. We previously reported that ADAR2 was downregulated in ESCC but its role was unclear. Thus, we report here that overexpression of ADAR2 can induce apoptosis in ESCC cell lines and inhibit tumor growth in vitro and in vivo. ADAR2 knockdown inhibited apoptosis in ADAR2 highly expressing tumor cells. RNA-seq assay showed that ADAR2, not ADAR1 or active-site-mutated ADAR2, could edit insulin-like growth factor binding protein 7 (IGFBP7) mRNA in ESCC. IGFBP7 knockdown or ADAR2 catalytic activity destruction abolished the pro-apoptotic function of ADAR2. Mechanistically, RNA editing may stabilize IGFBP7 protein by changing the protease recognition site of matriptase and this is essential for IGFBP7 to induce apoptosis. Western blotting revealed that ADAR2 overexpression could induce IGFBP7-dependent inhibition of Akt signaling. Thus, our data indicate that ADAR2 suppresses tumor growth and induces apoptosis by editing and stabilizing IGFBP7 in ESCC, and this may represent a novel therapeutic target for treating ESCC.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2017]版:
大类 | 3 区 医学
小类 | 3 区 肿瘤学
最新[2023]版:
大类 | 3 区 医学
小类 | 3 区 肿瘤学
第一作者:
第一作者机构: [1]Sun Yat Sen Univ, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Ctr Canc, Guangzhou 510060, Guangdong, Peoples R China; [2]Qingdao Univ, Affiliated Hosp, Cent Lab, Qingdao 266000, Shandong, Peoples R China;
通讯作者:
通讯机构: [1]Sun Yat Sen Univ, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Ctr Canc, Guangzhou 510060, Guangdong, Peoples R China; [5]Sun Yat Sen Univ, State Key Lab Oncol South China, Ctr Canc, Bldg 2,Room 903,651 Dongfeng Rd East, Guangzhou 510060, Guangdong, Peoples R China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:43378 今日访问量:0 总访问量:3120 更新日期:2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持:重庆聚合科技有限公司 地址:成都市人民南路四段55号